Fairooz Kabbinavar, MD, FACP

Equibles does not estimate personal net worth.

About Fairooz Kabbinavar, MD, FACP

Cardiff Oncology, Inc. reported in an 8-K filed February 2, 2023 that Fairooz Kabbinavar, MD, FACP was appointed chief medical officer (CMO). Cardiff Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cardiff Oncology, Inc. includes Mani Mohindru (CEO), Mani Mohindru, Ph.D. (CEO), Mark Erlander (CEO) and 7 others.

“Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as chief medical officer (CMO).”

Cardiff Oncology, Inc. Form 8-K, filed February 2, 2023 · Read the filing

Affiliation history

Cardiff Oncology, Inc. (CRDF)
SEC 8-K

Current
2023-02-02–present

Company network

Cardiff Oncology, Inc.

CRDF

Current role

Biotechnology · Healthcare

Leadership on record at Cardiff Oncology, Inc.

Recent activity

Executive change Appointed: chief medical officer (CMO) Cardiff Oncology, Inc. (CRDF)
2023-02-02